Kane Biotech Inc (CVE:KNE) Director Marc Edwards acquired 250,000 shares of Kane Biotech stock in a transaction dated Thursday, October 25th. The shares were bought at an average cost of C$0.07 per share, with a total value of C$17,500.00.
CVE KNE opened at C$0.08 on Friday. Kane Biotech Inc has a 12-month low of C$0.06 and a 12-month high of C$0.15.
Kane Biotech (CVE:KNE) last posted its quarterly earnings results on Tuesday, August 21st. The company reported C($0.01) earnings per share (EPS) for the quarter. Kane Biotech had a negative net margin of 1,545.33% and a negative return on equity of 172.74%. The business had revenue of C$0.10 million during the quarter.
Kane Biotech Inc, a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; shampoo for dogs, cats, and horses under the Alosera trademark; and pet oral care solutions under the StrixNB and bluestem trademarks.
Read More: Insider Trading
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.